1. Review the history and biology of the Ras oncogene.
2. Discuss prior drug development strategies in anti-Ras therapy.
3. Present recent trial data on a KRAS (G12C) inhibitor.
02/13/2020 - 8:00am to 9:15am CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Michael J. Breen, M.D., Ph.D.